Advertisement
CNC vs HUM
Which Stock Would AI Choose? Centene Corporation (CNC) vs. Humana Inc. (HUM) Stock Comparison
Key Takeaways
- Centene has faced a sharp deterioration in profitability, with its health benefits ratio (HBR) — the percentage of premiums spent on medical care — spiking to 93%, forcing a dramatic downward revision of earnings guidance in recent months.
- Humana raised its full-year adjusted EPS (earnings per share) outlook to approximately $17.00, supported by stabilizing medical cost trends and stronger-than-expected Medicare Advantage retention.
- Centene carries a significantly lower forward price-to-earnings multiple, reflecting deep market skepticism about its near-term recovery path, while Humana commands a premium valuation backed by more consistent execution.
- Both companies face regulatory and utilization headwinds, but Humana's CenterWell diversification into primary care, pharmacy, and home health provides a secondary growth engine that Centene lacks.
- Humana pays a regular dividend with a yield around 1.35%, whereas Centene has historically returned no capital to shareholders via dividends.
- Over the trailing twelve months, Humana has materially outperformed Centene in total shareholder return, reinforcing a divergence in market sentiment between the two managed-care peers.
Introduction
Investors navigating the managed-care landscape frequently compare CNC and HUM because both companies are deeply entrenched in government-sponsored healthcare programs — yet they have produced starkly different outcomes in recent quarters. Centene Corporation dominates Medicaid and the Affordable Care Act (ACA) Marketplace, while Humana Inc. holds a leading position in Medicare Advantage (MA), a rapidly growing segment serving America's aging population. This stock comparison examines how each company has navigated medical cost inflation, regulatory shifts, and competitive pressures. For traders and long-term investors alike, understanding the contrast between these two healthcare insurers offers a lens into broader sector dynamics and risk-reward trade-offs.
CNC Overview and Recent Performance
CNC, headquartered in St. Louis, Missouri, is one of the largest managed-care organizations in the United States, serving approximately 28 million members across Medicaid, Medicare Advantage, the ACA Marketplace, Tricare, and correctional healthcare. The company built its scale through a series of transformative acquisitions — including Health Net, WellCare, and Magellan Health — creating a diversified government-contract portfolio that historically generated steady revenue growth.
In recent months, however, Centene's earnings profile has come under severe pressure. The company's HBR surged to 93% in its most recent quarterly report, reflecting a convergence of unfavorable developments: lower-than-expected risk-adjustment transfer payments from the ACA Marketplace, elevated medical utilization in Medicaid driven by behavioral health and high-cost drugs, and a premium deficiency reserve taken in Medicare Advantage. These factors culminated in Centene withdrawing its full-year earnings guidance — a move that triggered a significant repricing of the stock. A securities class-action lawsuit was subsequently filed, alleging that the company had disseminated misleadingly optimistic statements about enrollment and morbidity trends. With long-term debt standing at roughly $17.6 billion and management acknowledging that margin recovery will require repricing Marketplace plans and stabilizing MA operations over multiple years, Centene currently trades at a deep discount to its historical valuation multiples.
HUM Overview and Recent Performance
HUM, based in Louisville, Kentucky, is synonymous with Medicare Advantage, commanding nearly 21% of the MA market with approximately 3.54 million individual MA members. The company's strategy extends beyond traditional insurance: its CenterWell segment — encompassing value-based primary care, pharmacy solutions, and home health services — has become a meaningful contributor to both revenue diversification and clinical outcomes. This integrated care model aims to capture efficiencies across the healthcare delivery chain.
In the most recent quarter, Humana reported adjusted EPS of $6.27 on revenue of $32.4 billion, both exceeding consensus analyst estimates. Management raised its full-year adjusted EPS guidance to approximately $17.00 and lifted its revenue target to at least $128 billion, signaling confidence in its pricing discipline and cost-management initiatives. The company is simultaneously reshaping its membership base by exiting unprofitable plans and counties, which will likely reduce individual MA membership by up to 500,000 members in the near term but is expected to improve long-term margin quality. Humana has also faced challenges: a federal judge dismissed its lawsuit seeking to reverse Medicare bonus-payment cuts tied to quality Star Ratings, though the company retains the right to appeal. Despite these headwinds, Humana has demonstrated superior relative performance in recent market activity, buoyed by stabilizing medical cost trends and stronger-than-anticipated MA retention.
Trending AI Robots
In a market environment where managed-care stocks can swing dramatically on regulatory news, actuarial adjustments, and utilization surprises, traders are increasingly turning to AI-driven tools for timely decision-making. Tickeron's Trending AI Robots page curates a select group of AI-powered trading bots from a broader universe of hundreds — each bot designed with distinct trading strategies, timeframes, and risk parameters, targeting thousands of different tickers across the equity landscape. Only those bots demonstrating statistically robust performance and alignment with prevailing market conditions earn a spot in this featured section. The bots cover an array of trading styles, from short-term momentum plays to longer-duration trend-following approaches, with performance metrics and win rates transparently displayed. For traders seeking to complement fundamental analysis with quantitative, AI-generated signals, exploring the Trending AI Robots section offers a practical starting point.
Head-to-Head Comparison
While both CNC and HUM operate in government-sponsored healthcare, their business-model emphases create fundamentally different risk profiles. Centene is heavily weighted toward Medicaid and the ACA Marketplace — programs that serve lower-income and subsidized populations with thinner per-member margins. This makes the company highly sensitive to changes in medical utilization rates and risk-adjustment calculations. Humana, by contrast, derives the bulk of its revenue from Medicare Advantage, where members are seniors with more predictable, though higher-cost, healthcare needs. The MA segment benefits from strong demographic tailwinds as the U.S. population ages.
On growth drivers, Centene is in recovery mode — repricing contracts, managing elevated medical costs, and targeting Medicare Advantage breakeven by 2027. Humana is in optimization mode — pruning unprofitable membership while expanding CenterWell's higher-margin care-delivery services. On risk factors, Centene faces immediate litigation risk from the securities class action, potential Medicaid enrollment erosion under evolving federal policy, and the execution risk of a multi-year turnaround. Humana's risks center on Star Ratings litigation, persistent MA membership attrition from plan exits, and elevated benefit and operating cost ratios.
Market sentiment clearly diverges: Centene trades at a forward P/E (price-to-earnings ratio) well below the industry median, reflecting deep investor skepticism, while Humana commands a premium multiple supported by more stable earnings visibility. Humana also returns capital to shareholders through a regular dividend, whereas Centene does not — a meaningful differentiator for income-oriented portfolios.
Tickeron AI Verdict
Based on observable trend consistency, relative earnings momentum, and catalyst positioning, Tickeron's AI-driven analysis would likely favor HUM over CNC in the current environment. Humana's combination of upwardly revised guidance, a diversified revenue base through CenterWell, and more predictable Medicare Advantage demographics presents a comparatively smoother trajectory, even as both companies navigate sector-wide medical cost pressures. Centene's significantly compressed valuation could offer asymmetric upside if its turnaround gains traction, but the AI framework would weigh the prevailing trend direction, earnings revision momentum, and volatility profile — all of which currently tilt in Humana's favor. This probabilistic assessment reflects current observable data rather than a definitive forecast, and market conditions can shift as new information emerges.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CNC is a Hold and HUM is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CNC’s FA Score shows that 1 FA rating(s) are green whileHUM’s FA Score has 3 green FA rating(s).
- CNC’s FA Score: 1 green, 4 red.
- HUM’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CNC’s TA Score shows that 3 TA indicator(s) are bullish while HUM’s TA Score has 3 bullish TA indicator(s).
- CNC’s TA Score: 3 bullish, 4 bearish.
- HUM’s TA Score: 3 bullish, 5 bearish.
Price Growth
CNC (@Managed Health Care) experienced а -4.56% price change this week, while HUM (@Managed Health Care) price change was -2.67% for the same time period.
The average weekly price growth across all stocks in the @Managed Health Care industry was -3.04%. For the same industry, the average monthly price growth was +0.36%, and the average quarterly price growth was +26.69%.
Reported Earning Dates
CNC is expected to report earnings on Jul 28, 2026.
HUM is expected to report earnings on Jul 29, 2026.
Industries' Descriptions
@Managed Health Care (-3.04% weekly)Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.
| CNC | HUM | CNC / HUM | |
| Capitalization | 31.3B | 46.7B | 67% |
| EBITDA | -4.44B | N/A | - |
| Gain YTD | 54.095 | 53.133 | 102% |
| P/E Ratio | 9.06 | 41.55 | 22% |
| Revenue | 198B | 137B | 145% |
| Total Cash | 23.7B | N/A | - |
| Total Debt | 16.4B | 14B | 117% |
CNC | HUM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 64 | 88 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 59 Fair valued | 11 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 95 | |
PRICE GROWTH RATING 1..100 | 2 | 2 | |
P/E GROWTH RATING 1..100 | 69 | 8 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
HUM's Valuation (11) in the Managed Health Care industry is somewhat better than the same rating for CNC (59). This means that HUM’s stock grew somewhat faster than CNC’s over the last 12 months.
HUM's Profit vs Risk Rating (100) in the Managed Health Care industry is in the same range as CNC (100). This means that HUM’s stock grew similarly to CNC’s over the last 12 months.
HUM's SMR Rating (95) in the Managed Health Care industry is in the same range as CNC (98). This means that HUM’s stock grew similarly to CNC’s over the last 12 months.
HUM's Price Growth Rating (2) in the Managed Health Care industry is in the same range as CNC (2). This means that HUM’s stock grew similarly to CNC’s over the last 12 months.
HUM's P/E Growth Rating (8) in the Managed Health Care industry is somewhat better than the same rating for CNC (69). This means that HUM’s stock grew somewhat faster than CNC’s over the last 12 months.
| CNC | HUM | |
|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 66% |
| Stochastic ODDS (%) | 3 days ago 60% | 3 days ago 69% |
| Momentum ODDS (%) | 3 days ago 62% | 3 days ago 64% |
| MACD ODDS (%) | 3 days ago 70% | 3 days ago 69% |
| TrendWeek ODDS (%) | 3 days ago 66% | 3 days ago 65% |
| TrendMonth ODDS (%) | 3 days ago 66% | 3 days ago 62% |
| Advances ODDS (%) | 13 days ago 61% | 12 days ago 61% |
| Declines ODDS (%) | 3 days ago 63% | 3 days ago 66% |
| BollingerBands ODDS (%) | 3 days ago 71% | 3 days ago 81% |
| Aroon ODDS (%) | 3 days ago 70% | 3 days ago 61% |
Advertisement
CNC and
Correlation & Price change
A.I.dvisor indicates that over the last year, CNC has been closely correlated with MOH. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if CNC jumps, then MOH could also see price increases.
HUM and
Correlation & Price change
A.I.dvisor indicates that over the last year, HUM has been loosely correlated with UNH. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if HUM jumps, then UNH could also see price increases.